A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs AZD 3965 (Primary)
- Indications Diffuse large B cell lymphoma; Gastric cancer; Lymphoma; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results (n=35) assessing the maximum tolerated dose of in AZD3965 in patients with advanced solid tumours, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 04 Dec 2013 Accrual to date is 9% according to United Kingdom Clinical Research Network record.